Pathophysiological role of neutrophils in acute myocardial infarction

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 501-514

  Carbone, Federico ^a   Nencioni, Alessio ^a   Mach, François ^b   Vuilleumier, Nicolas ^b,c   Montecucco, Fabrizio ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Geneva University Hospitals ^*  (Switzerland)

Author keywords

Acute myocardial infarction; Atherosclerosis; Inflammation; Neutrophils

Indexed keywords

CHOLESTEROL; ELASTASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RANTES; REACTIVE OXYGEN METABOLITE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOPLASTY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; DISEASE SEVERITY; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; IMMUNOCOMPETENT CELL; NEOINTIMA; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; ANIMALS; ATHEROSCLEROSIS; CHEMOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; ISCHEMIA; LIPOPROTEINS, HDL; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHIL INFILTRATION; NEUTROPHILS; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; REACTIVE OXYGEN SPECIES;

EID: 84883245785     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-03-0211     Document Type: Article

References (207)

1. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8: 1211-1217.
2. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol 2007; 18: 492-499.
3. Hulten EA, et al. Prognostic value of cardiac computed tomography angiography: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 57: 1237-1247.
4. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013; 339: 161-166.
5. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012; 110: 875-888.
6. Hoffman M, et al. Leukocytes and coronary heart disease. Atherosclerosis 2004; 172: 1-6.
7. Coller BS. Leukocytosis and ischaemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol 2005; 25: 658-670.
8. Guasti L, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb Haemost 2011; 106: 591-599.
9. Dinerman JL, et al. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 1990; 15: 1559-1563.
10. Bell D, et al. Inflammatory response, neutrophil activation, and free radical production after acute myocardial infarction: effect of thrombolytic treatment. Br Heart J 1990; 63: 82-87.
11. Mazzone A, et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993; 88: 358-363.
12. Takeshita S, et al. Systemic inflammatory responses in acute coronary syndrome: increased activity observed in polymorphonuclear leukocytes but not T lymphocytes. Atherosclerosis 1997; 135: 187-192.
13. Leckie MJ, et al. Automated quantitation of peripheral blood neutrophil activation in patients with myocardial ischaemia. Int J Cardiol 2004; 95: 307-313.
14. Avanzas P, et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 2004; 90: 847-852.
15. Avanzas P, et al. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis 2004; 175: 151-157.
16. Haumer M, et al. Association of neutrophils and future cardiovascular events in patients with peripheral artery disease. J Vasc Surg 2005; 41: 610-617.
17. Grau AJ, et al. Leukocyte count as an independent predictor of recurrent ischaemic events. Stroke 2004; 35: 1147-1152.
18. Gillum RF, et al. Counts of neutrophils, lymphocytes, and monocytes, causespecific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol 2005; 15: 266-271.
19. Horne BD, et al.; Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45: 1638-1643.
20. Nijm J, et al. Circulating levels of proinflammatory cytokines and neutrophilplatelet aggregates in patients with coronary artery disease. Am J Cardiol 2005; 95: 452-456.
21. Tsai JC, et al. Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischaemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2007; 23: 111-118.
22. Zazula AD, et al. An assessment of neutrophils/lymphocytes ratio in patients suspected of acute coronary syndrome. Arq Bras Cardiol 2008; 90: 31-36.
23. Papa A, et al. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta 2008; 395: 27-31.
24. Karabinos I, et al. Neutrophil count on admission predicts major in-hospital events in patients with a non-ST-segment elevation acute coronary syndrome. Clin Cardiol 2009; 32: 561-568.
25. Poludasu S, et al. Neutrophil to lymphocyte ratio as a predictor of long-term mortality in African Americans undergoing percutaneous coronary intervention. Clin Cardiol 2009; 32: E6-E10.
26. Setianto BY, et al. Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome. Heart Vessels 2010; 25: 282-287.
27. Muhmmed Suliman MA, et al. Predictive value of neutrophil to lymphocyte ratio in outcomes of patients with acute coronary syndrome. Arch Med Res 2010; 41: 618-622.
28. Husser O, et al. White blood cell subtypes after STEMI: temporal evolution, association with cardiovascular magnetic resonance--derived infarct size and impact on outcome. Inflammation 2011; 34: 73-84.
29. Park BJ, et al. Relationship of neutrophil-lymphocyte ratio with arterial stiffness and coronary calcium score. Clin Chim Acta 2011; 412: 925-929.
30. Hartaigh B, et al. Which leukocyte subsets predict cardiovascular mortality? From the LUdwigshafen RIsk and Cardiovascular Health (LURIC) Study. Atherosclerosis 2012; 224: 161-169.
31. Arbel Y, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis 2012; 225: 456-460.
32. Kaya MG, et al. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: A prospective, multicenter study. Int J Cardiol 2012; epub ahead of print.
33. Park JJ, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013; 111: 636-642.
34. Hopps E, et al. Pathophysiology of polymorphonuclear leukocyte in arterial hypertension. Clin Hemorheol Microcirc 2009; 41: 209-218.
35. Shurtz-Swirski R, et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care 2001; 24: 104-110.
36. Rudolph TK, Rudolph V, Baldus S. Contribution of myeloperoxidase to smoking-dependent vascular inflammation. Proc Am Thorac Soc 2008; 5: 820-823.
37. Soehnlein O, et al. Functional alterations of myeloid cell subsets in hyperlipidaemia: relevance for atherosclerosis. J Cell Mol Med 2009; 13: 4293-4303.
38. Guasti L, et al. Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. Sleep Breath 2011; 15: 3-11.
39. Turkmen K, et al. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail 2012; 34: 155-159.
40. Mehta J, et al. Neutrophil function in ischaemic heart disease. Circulation 1989; 79: 549-556.
41. De Servi S, et al. Clinical and angiographic correlates of leukocyte activation in unstable angina. J Am Coll Cardiol 1995; 26: 1146-1150.
42. Amaro A, et al. Activity of leucocyte elastase in women with coronary artery disease documented using angiography. J Cardiovasc Risk 1995; 2: 149-153.
43. Biasucci LM, et al. Delayed neutrophil apoptosis in patients with unstable angina: relation to C-reactive protein and recurrence of instability. Eur Heart J 2009; 30: 2220-2225.
44. Kosar F, et al. Plasma leukocyte elastase concentration and coronary artery disease. Angiology 1998; 49: 193-201.
45. Smith FB, et al. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J 2000; 21: 1607-1613.
46. Zhang R, et al. Association between myeloperoxidase levels and risk of coronary artery disease. J Am Med Assoc 2001; 286: 2136-2142.
47. Garlichs CD, et al. Delay of neutrophil apoptosis in acute coronary syndromes. J Leukoc Biol 2004; 75: 828-835.
48. Buffon A, et al. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
49. Sánchez de Miguel L, et al. Nitric oxide production by neutrophils obtained from patients during acute coronary syndromes: expression of the nitric oxide synthase isoforms. J Am Coll Cardiol 2002; 39: 818-825.
50. Smith C, et al. Increased Levels of Neutrophil-Activating Peptide-2 in Acute Coronary Syndromes. J Am Coll Cardiol 2006; 48: 1591-1599.
51. Mocatta TJ, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007; 49: 1993-2000.
52. Roman RM, et al. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis 2010; 21: 129-136.
53. Naruko T, et al. Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina. Heart 2010; 96: 1716-1722.
54. Cojocaru IM, et al. Plasma myeloperoxidase levels in patients with acute ischaemic stroke. Rom J Intern Med 2010; 48: 101-104.
55. Kafkas N, et al. Serum levels of gelatinase associated lipocalin as indicator of the inflammatory status in coronary artery disease. Int J Inflam 2012; 2012: 189797.
56. Salonen I, et al. Serum myeloperoxidase is independent of the risk factors of atherosclerosis. J Clin Invest 2012; 23: 251-258.
57. Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 2010; 10: 427-439.
58. Quercioli A, et al. Receptor activator of NF-κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost 2012; 107: 124-139.
59. Zernecke A, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008; 102: 209-217.
60. Drechsler M, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837-1845.
61. van Leeuwen M, Gijbels MJJ, Duijvestijn A, et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/-mice. Arterioscler Thromb Vasc Biol 2008; 28: 84-89.
62. Hosokawa T, et al. Neutrophil infiltration and oxidant-production in human atherosclerotic carotid plaques. Histol Histopathol 2011; 26: 1-11.
63. Rotzius P, et al. ApoE-/-/Lysozyme MEGFP/EGFP mice as a versatile model to study monocyte and neutrophil trafficking in atherosclerosis. Atherosclerosis 2009; 202: 111-118.
64. Lansky AJ, et al. Gender and the Extent of Coronary Atherosclerosis, Plaque Composition, and Clinical Outcomes in Acute Coronary Syndromes. J Clin Invest 2012; 5: S62-S72.
65. Virmani R, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-1275.
66. Richardson PD, et al. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-944.
67. Virmani R, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47: C13-18.
68. Burke AP, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-1282.
69. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41: 15S-22S.
70. Naruko T, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106: 2894-2900.
71. Ionita MG, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 2010; 30: 1842-1848.
72. Leclercq A, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007; 82: 1420-1429.
73. Borregaard N, et al. Neutrophil granules: a library of innate immunity proteins. Trends Immunol 2007; 28: 340-345.
74. Galis ZS, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodelling. Circ Res 2002; 91: 852-859.
75. Choi ET, et al. Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 1020-1025.
76. Kuzuya M, et al. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 1120-1125.
77. Allan JA, et al. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 1995; 309: 299-306.
78. Bäck M, et al. Matrix Metalloproteinases in Atherothrombosis. Prog Cardiovasc Dis 2010; 52: 410-428.
79. Dorweiler B, et al. Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilising enzymes in an experimental model of human neo-intima. Thromb Haemost. 2008; 99: 373-381.
80. Laxton RC, et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res 2009; 105: 921-929.
81. Dollery CM, et al. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 2003; 107: 2829-2836.
82. Henriksen PA, Sallenave JM. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. Int J Biochem Cell Biol 2008; 40: 1095-1100.
83. Moreno JA, et al. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur Heart J. 2012; 33: 252-263.
84. Rao NV, et al. Characterisation of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. J Biol Chem 1991; 266: 9540-9548.
85. Pezzato E. Proteinase-3 directly activates MMP-2 and degrades gelatin and Matrigel; differential inhibition by (-)epigallocatechin-3-gallate. J Leukoc Biol 2003; 74: 88-94.
86. Kuckleburg CJ, et al. Proteinase 3 contributes to transendothelial migration of NB1-positive neutrophils. J Immunol 2012; 188: 2419-2426.
87. Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 2007; 219: 88-102.
88. Prokopowicz Z, et al. Neutrophil Myeloperoxidase: Soldier and Statesman. Arch Immunol Ther Exp 2012; 60: 43-54.
89. Daugherty A, et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-444.
90. Malle E, et al. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalisation of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 2000; 267: 4495-4503.
91. Hochholzer W, et al. Novel biomarkers in cardiovascular disease: Update 2010. Am Heart J 2010; 160: 583-594.
92. Zhang R, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 2002; 277: 46116-46122.
93. Podrez EA, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105: 1095-1108.
94. Fu X, et al. Hypochlorous acid oxygenates the cysteine switch domain of promatrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001; 276: 41279-41287.
95. Kebir El D, et al. Myeloperoxidase delays neutrophil apoptosis through CD11b/CD18 integrins and prolongs inflammation. Circ Res 2008; 103: 352-359.
96. Penn MS, et al. Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation. Blood 2000; 96: 3056-3063.
97. Drechsler M, et al. Neutrophilic granulocytes-promiscuous accelerators of atherosclerosis. Thromb Haemost 2011; 106: 839-848.
98. Ouyang W, et al. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-467.
99. Pejnovic N, et al. Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet. Mol Immunol 2009; 47: 37-45.
100. Smith E, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010; 121: 1746-1755.
101. Liao YH, et al. Interleukin-17A contributes to myocardial ischaemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol 2012; 59: 420-429.
102. Pelletier M, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010; 115: 335-343.
103. Liuzzo G, et al. Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J 2013; 34: 556-559.
104. Lee A, et al. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993; 54: 283-288.
105. Yamashiro S, et al. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 2000; 96: 3958-3963.
106. Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. Int Immunopharmacol 2010; 10: 1325-1334.
107. Iking-Konert C, et al. Transdifferentiation of polymorphonuclear neutrophils: acquisition of CD83 and other functional characteristics of dendritic cells. J Mol Med 2001; 79: 464-474.
108. Abi Abdallah DS, et al. Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol 2011; 23: 317-326.
109. Farb A, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-1363.
110. Mazor R, et al. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis 2008; 197: 937-943.
111. Eiserich JP, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998; 391: 393-397.
112. Förstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010; 459: 923-939.
113. Calcerrada P, et al. Nitric oxide-derived oxidants with a focus on peroxynitrite: molecular targets, cellular responses and therapeutic implications. Curr Pharm Des 2011; 17: 3905-3932.
114. Hazell LJ, et al. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996; 97: 1535-1544.
115. Sugiyama S, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidasemediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 1309-1314.
116. Rowe RG, Weiss SJ. Breaching the basement membrane: who, when and how? Trends Cell Biol 2008; 18: 560-574.
117. Montecucco F, et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-421.
118. Soehnlein O, et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 2008; 112: 1461-1471.
119. Chertov O, et al. Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med 1997; 186: 739-747.
120. Sun R, et al. Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J Immunol 2004; 173: 428-436.
121. Ott I, et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996; 94: 1239-1246.
122. Adlbrecht C, et al. Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost 2007; 97: 642-649.
123. Badrnya S, et al. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb Haemost 2012; 108: 719-729.
124. Huo Y, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67.
125. Vanichakarn P, et al. Neutrophil CD40 enhances platelet-mediated inflammation. Thromb Res 2008; 122: 346-358.
126. Li G, et al. CD40 Ligand Promotes Mac-1 Expression, Leukocyte Recruitment, and Neointima Formation after Vascular Injury. J Clin Invest 2008; 172: 1141-1152.
127. Fuchs TA, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
128. King SB III, et al. Revascularisation for Coronary Artery Disease: Stents Versus Bypass Surgery. Annu Rev Med 2010; 61: 199-213.
129. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 2009; 73: 615-621.
130. Libby P, et al. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86: III47-52.
131. Rogers C, et al. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998; 95: 10134-10139.
132. Simon DI, et al. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. J Clin Invest 2000; 105: 293-300.
133. Hayashi S, et al. Roles of P-selectin in inflammation, neointimal formation, and vascular remodelling in balloon-injured rat carotid arteries. Circulation 2000; 102: 1710-1717.
134. Wang K, et al. Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury. Arterioscler Thromb Vasc Biol 2005; 25: 1584-1589.
135. Hristov M, et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; 100: 590-597.
136. Liehn EA, et al. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 1891-1896.
137. Xing D, et al. Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury. Circulation 2012; 125: 1533-1541.
138. Soehnlein O, et al. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med 2011; 3: 103ra98.
139. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012; 110: 159-173.
140. Arslan F, et al. Myocardial ischaemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010; 121: 80-90.
141. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011; 108: 1133-1145.
142. Andrassy M, et al. High-mobility group box-1 in ischaemia-reperfusion injury of the heart. Circulation 2008; 117: 3216-3226.
143. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971; 133: 885-900.
144. Meldrum DR, et al. Hydrogen peroxide induces tumor necrosis factor alphamediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery 1998; 124: 291-296.
145. Sellak H, et al. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood 1994; 83: 2669-2677.
146. Gordon JW, et al. Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ Res 2011; 108: 1122-1132.
147. Kleinbongard P, et al. TNFalpha in atherosclerosis, myocardial ischaemia/reperfusion and heart failure. Pharmacol Ther 2010; 127: 295-314.
148. Bujak M, et al. Interleukin-1 receptor type I signalling critically regulates infarct healing and cardiac remodelling. Am J Pathol 2008; 173: 57-67.
149. Frangogiannis NG. Chemokines in ischaemia and reperfusion. Thromb Haemost 2007; 97: 738-747.
150. Dewald O, et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 2004; 164: 665-677.
151. Briaud SA, et al. Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice. Am J Physiol Heart Circ Physiol 2001; 280: H60-67.
152. Metzler B, et al. Mouse model of myocardial remodelling after ischaemia: role of intercellular adhesion molecule-1. Cardiovasc Res 2001; 49: 399-407.
153. Bournazou I, et al. Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin. J Clin Invest 2009; 119: 20-32.
154. Nahrendorf M, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-3047.
155. Dutta P, et al. Myocardial infarction accelerates atherosclerosis. Nature 2012; 487: 325-329.
156. Jordan J. The role of neutrophils in myocardial ischaemia-reperfusion injury. J Clin Invest 1999; 43: 860-878.
157. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994; 28: 1301-1311.
158. Frame LH, et al. Early membrane damage during coronary reperfusion in dogs. Detection by radiolabeled anticardiac myosin (Fab')2. J Clin Invest 1983; 72: 535-544.
159. Farb A, et al. Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. J Am Coll Cardiol 1993; 21: 1245-1253.
160. Rochitte CE, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998; 98: 1006-1014.
161. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61: 481-497.
162. Liehn EA, et al. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol 2011; 58: 2415-2423.
163. Walter DH, et al. Impaired CXCR4 signalling contributes to the reduced neovascularisation capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res 2005; 97: 1142-1151.
164. Corsini A, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428.
165. Dunzendorfer S, et al. Mevalonate-Dependent Inhibition of Transendothelial Migration and Chemotaxis of Human Peripheral Blood Neutrophils by Pravastatin. Circ Res 1997; 81: 963-969.
166. Kaneider NC, et al. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 2001; 158: 23-33.
167. Chello M, et al. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg 2007; 83: 1374-1380.
168. Sugano R, et al. Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid-lowering therapies. Arterioscler Thromb Vasc Biol 2005; 25: 1262-1267.
169. Eccles KA, et al. Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 2008; 200: 69-79.
170. Walter T, et al. Effect of atorvastatin on cellular adhesion molecules on leukocytes in patients with normocholesterolemic coronary artery disease. In Vivo. 2010; 24: 189-193.
171. Kinsella A, et al. The impact of high-dose statin therapy on transendothelial neutrophil migration and serum cholesterol levels in healthy male volunteers. J Clin Invest 2011; 67: 1103-1108.
172. Omi H, et al. Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. J Clin Invest 2003; 65: 118-124.
173. Okouchi M, et al. Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation. J Clin Invest 2003; 17: 380-386.
174. Bandoh T, et al. Antioxidative Potential of Fluvastatin via the Inhibition of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase Activity. J Clin Invest 2003; 26: 818-822.
175. Kowalski J, et al. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 2006; 48: 143-147.
176. Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109: II18-26.
177. Alblas J, et al. Activation of Rhoa and ROCK are essential for detachment of migrating leukocytes. Mol Biol Cell 2001; 12: 2137-2145.
178. Maher BM, et al. Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol 2009; 85: 186-193.
179. Kaneider NC, et al. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol 2002; 22: 1029-1035.
180. Nakamura K, et al. Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 2009; 206: 355-361.
181. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007; 100: n32-40.
182. Murphy AJ, et al. Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 1333-1341.
183. Kannan KB, et al. Free cholesterol alters lipid raft structure and function regulating neutrophil Ca2+ entry and respiratory burst: correlations with calcium channel raft trafficking. J Immunol 2007; 178: 5253-5261.
184. Shao D, et al. Lipid rafts determine efficiency of NADPH oxidase activation in neutrophils. FEBS Lett 2003; 550: 101-106.
185. Furlaneto CJ, et al. Apolipoproteins A-I and A-II downregulate neutrophil functions. Lipids 2002; 37: 925-928.
186. Liao X-L, et al. Neutrophils activation can be diminished by apolipoprotein A-I. Life Sci 2005; 77: 325-335.
187. Nicholls SJ, et al. Reconstituted high-density lipoproteins inhibit the acute prooxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005; 111: 1543-1550.
188. Puranik R, et al. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 2008; 196: 240-247.
189. Woollard KJ, et al. Pathophysiological levels of soluble P-selectin mediate adhesion of leukocytes to the endothelium through Mac-1 activation. Circ Res 2008; 103: 1128-1138.
190. Pierini LM, et al. Membrane lipid organisation is critical for human neutrophil polarisation. J Biol Chem 2003; 278: 10831-10841.
191. Itoh S, et al. Redistribution of P-selectin glycoprotein ligand-1 (PSGL-1) in chemokine-treated neutrophils: a role of lipid microdomains. J Leukoc Biol 2007; 81: 1414-1421.
192. Oh H, et al. Membrane cholesterol is a biomechanical regulator of neutrophil adhesion. Arterioscler Thromb Vasc Biol 2009; 29: 1290-1297.
193. Yvan-Charvet L, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328: 1689-1693.
194. Murphy AJ, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011; 121: 4138-4149.
195. Westerterp M, et al. Regulation of hematopoietic stem and progenitor cell mobilisation by cholesterol efflux pathways. Cell Stem Cell 2012; 11: 195-206.
196. Murphy PM, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-176.
197. Montecucco F, et al. Induction of neutrophil chemotaxis by leptin: crucial role for p38 and Src kinases. Ann NY Acad Sci 2006; 1069: 463-471.
198. Braunersreuther V, et al. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol 2010; 48: 789-798.
199. Braunersreuther V, et al. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 2008; 28: 1090-1096.
200. Mahler DA, et al. Efficacy and safety of a monoclonal antibody recognising interleukin-8 in COPD: a pilot study. Chest 2004; 126: 926-934.
201. Montecucco F, et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J 2012; 33: 1964-1974.
202. Montecucco F, et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischaemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol 2010; 30: 1371-1377.
203. Widdowson KL, et al. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem 2004; 47: 1319-1321.
204. Tarzami ST, et al. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischaemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 2003; 108: 2387-2392.
205. Liehn EA, et al. Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction. J Cell Mol Med 2008; 12: 496-506.
206. Montecucco F, et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid. Redox Signal 2013; 18: 630-641.
207. Bauer I, et al. The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem 2012; 287: 40924-40937.